Lakefront Biotherapeutics NV
GLPGF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001421876
No open-market purchases or sales by Lakefront Biotherapeutics NV insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q3 2026; no superinvestor holds it.
Other share classesLKFT
- Currency
- EUR
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:06 PM ET
Amounts are in EUR, the currency Lakefront Biotherapeutics NV reports in. Lines marked ≈ US$ convert key figures to US dollars.
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F |
| Reported | – | – | – | – | – |
| Revenue | EUR 1.11B≈ US$1.26B | EUR 275.6M≈ US$298.3M | EUR 239.7M≈ US$259.3M | EUR 505.3M≈ US$532.3M | EUR 484.8M≈ US$573.6M |
| Cost of revenue | EUR 29.7M | EUR 34.9M | – | EUR 12.1M | EUR 1.63M |
| Research and development | EUR 459.4M | EUR 335.5M | EUR 241.3M | EUR 515.1M | EUR 491.7M |
| Selling, general and administrative | EUR 147.3M | EUR 117.2M | EUR 128.3M | EUR 144.9M | EUR 140.9M |
| Operating income | EUR 295.0M | EUR -188.3M | EUR -88.3M | EUR -267.5M | EUR -165.6M |
| Interest expense | EUR 1.03M | EUR 911.0K | EUR 1.77M | EUR 6.97M | EUR 11.7M |
| Income tax | EUR -18.6M | EUR -1.80M | EUR 9.61M | EUR 2.84M | EUR 2.42M |
| Net income | EUR 320.9M≈ US$362.8M | EUR 74.1M≈ US$80.2M | EUR 211.7M≈ US$229.0M | EUR -218.0M≈ US-$229.6M | EUR -103.2M≈ US-$122.1M |
| EPS, basic | EUR 4.87 | EUR 1.12 | EUR 3.21 | EUR -3.32 | EUR -1.58 |
| EPS, diluted | EUR 4.87 | EUR 1.12 | EUR 3.21 | EUR -3.32 | EUR -1.58 |
| Weighted shares, basic | 65.9M | 65.9M | 65.9M | 65.7M | 65.5M |
| Weighted shares, diluted | 65.9M | 65.9M | – | – | – |
| Margins and growth | |||||
| Operating margin | 26.5% | -68.3% | -36.8% | -52.9% | -34.2% |
| Net margin | 28.9% | 26.9% | 88.3% | -43.1% | -21.3% |
| Revenue growth, year over year | +303.5% | +15.0% | −52.6% | +4.2% | +1.4% |
| Net income growth, year over year | +333.1% | −65.0% | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F |
| Reported | – | – | – | – | – |
| Cash and equivalents | EUR 87.9M | EUR 64.2M | EUR 166.8M | EUR 508.1M | EUR 2.23B |
| Accounts receivable | EUR 9.57M | EUR 32.5M | EUR 17.5M | EUR 28.2M | EUR 91.8M |
| Inventory | EUR 22.5M | EUR 51.2M | EUR 74.0M | EUR 52.9M | EUR 20.6M |
| Total current assets | EUR 3.08B | EUR 3.34B | EUR 3.86B | EUR 4.24B | EUR 4.86B |
| Property, plant and equipment | EUR 71.9M | EUR 105.4M | EUR 111.2M | EUR 126.7M | EUR 105.7M |
| Goodwill | – | EUR 70.0M | EUR 69.6M | EUR 69.8M | – |
| Intangible assets | EUR 848.0K | EUR 164.9M | EUR 127.9M | EUR 146.4M | EUR 60.1M |
| Total assets | EUR 3.41B≈ US$4.00B | EUR 4.14B≈ US$4.28B | EUR 4.36B≈ US$4.82B | EUR 4.73B≈ US$5.06B | EUR 5.19B≈ US$5.88B |
| Accounts payable | EUR 104.6M | EUR 98.9M | EUR 135.2M | EUR 148.7M | EUR 137.4M |
| Total current liabilities | EUR 152.9M | EUR 335.1M | EUR 428.2M | EUR 522.5M | EUR 566.5M |
| Total liabilities | EUR 170.7M | EUR 1.24B | EUR 1.56B | EUR 2.21B | EUR 2.55B |
| Shareholders' equity | EUR 3.24B | EUR 2.90B | EUR 2.80B | EUR 2.53B | EUR 2.64B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F |
| Reported | – | – | – | – | – |
| Operating cash flow | EUR -257.5M≈ US-$291.1M | EUR -320.0M≈ US-$346.3M | EUR -406.0M≈ US-$439.1M | EUR -500.5M≈ US-$527.3M | EUR -503.8M≈ US-$596.0M |
| Capital expenditures | EUR 13.7M | EUR 16.7M | EUR 18.7M | EUR 27.4M | EUR 54.2M |
| Free cash flow | EUR -271.2M≈ US-$306.6M | EUR -336.7M≈ US-$364.4M | EUR -424.7M≈ US-$459.4M | EUR -527.9M≈ US-$556.1M | EUR -558.0M≈ US-$660.2M |
| Stock-based compensation | EUR 24.0M | EUR 19.9M | EUR 56.7M | EUR 88.5M | EUR 70.7M |
| Investing cash flow | EUR 288.8M | EUR 220.6M | EUR 71.2M | EUR -1.25B | EUR 541.2M |
| Financing cash flow | EUR -3.27M | EUR -4.92M | EUR -5.00M | EUR -1.49M | EUR -3.88M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 2.2% | 7.2% | 23.7% | 17.5% | 14.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Dec 31, 2025 | 65.9M | 0.0% | SEC |
| Dec 31, 2024 | 65.9M | 0.0% | SEC |
| Dec 31, 2023 | 65.9M | +0.1% | SEC |
| Dec 31, 2022 | 65.8M | +0.4% | SEC |
| Dec 31, 2021 | 65.6M | +0.2% | SEC |
| Dec 31, 2020 | 65.4M | +1.2% | SEC |
| Dec 31, 2019 | 64.7M | +18.7% | SEC |
| Dec 31, 2018 | 54.5M | +6.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- ≈ US$ figures convert EUR at FRED H.10 exchange rates (Federal Reserve): the average rate over the period for income and cash flow, and the rate on the period-end date, or the last business day before it, for the balance sheet.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS. Their cover share count adds up the classes but only for the last few filings, so there can be a gap before them.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.